NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service central anti-infective clinical microbiology laboratory have announced a collaborative agreement that will provide the pharmaceutical industry with a brand-new antifungal resistance surveillance program termed STAR. In addition to the expertise provided by NTS and IHMA, STAR is heavily supported through affiliations with key opinion leader (KOL) laboratories throughout the world. As antifungal resistance rises and epidemiology changes, STAR will intimately monitor fluctuations and trends in antifungal resistance and epidemiology over time. It will be an excellent tool to serve authorities, biotechnology and pharmaceutical companies in the relentless fight against antifungal drug resistance. The clinical isolates prospectively collected through STAR will include all major yeasts (including the emerging pathogen Candida auris) and filamentous fungi, such as Aspergillus spp. as well as the rarer and highly invasive mold species such as Mucor spp., Rhizopus spp., among others.
The development of new antifungal agents is increasing. Consequently, STAR will support these drugs to ensure the fight against antifungal resistance will be more efficient and to gain precious time in reducing and eventually eliminating new resistance. The agreement between NTS and IHMA will allow all pharmaceutical and biotech companies access to the STAR program in a cost- and time-effective manner. "The STAR program is a one of a kind surveillance initiative profiling serious fungal infections, including Candida auris and Aspergillus, against common and experimental antifungals under development," said Dr. Mahmoud Ghannoum, Founder of NTS Ventures.
"The STAR surveillance program will provide valuable information regarding serious fungal infections and provide the medical community with up to date and pertinent information regarding antifungal agents," said Dr. Daniel Sahm, Chief Scientific Officer and VP of Global Microbiology Services at IHMA, Inc.
ABOUT NTS Ventures
NTS is based in Cleveland, OH and provides preclinical, clinical and translational services designed to bring antifungal, antibacterial and dermatology agents from discovery to market. NTS has the ability to support drug development in preclinical and clinical testing phases in order to satisfy FDA Investigational New Drug (IND) and New Drug Application (NDA) submissions. Over the past 25 years the NTS team has worked with a large range of entities including global Big Pharma, start up and growth stage biotech companies, full-spectrum CRO's as well as academic institutions.
For more information, please visit https://www.ntsventures.com.
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways. For more information, visit the IHMA website at: www.ihma.com
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method21.11.2019 17:00:00 CET | Press release
STOCKHOLM – November 21, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announce today that its proprietary Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”. ContextVision developed this method to automatically and more objectively outline specific structures in pathology images used for training deep learning algorithms. It identifies and highlights cancer areas and other structures by using multi-plex immunofluorescent staining. This enables development of algorithms based on objective data with high accuracy. “This patent protection is a milestone for ContextVision, and I´m so happy and proud to see this idea become reality. Thanks to a strong team effort we h
Auction details Inflation-linked bonds21.11.2019 16:20:00 CET | Press release
Auction date November 28, 2019 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2032-06-01 3111 SE0007045745 0.125% 500 Settlement date December 2, 2019 Bids have to be entered by 11.00 on November 28, 2019 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 firstname.lastname@example.org
Avance Gas – Invitation to Earnings Release Audio Webcast for the Third Quarter of 201921.11.2019 15:46:00 CET | Press release
Bermuda, 21 November 2019 - Avance Gas Holding Ltd (OSE: "AVANCE"), will on Tuesday 26 November 2019 release its unaudited results for the third quarter of 2019. In connection with the earnings release, an audio webcast and conference call will be held at 15:00 (CET). The webcast can be accessed at Avance Gas’ website www.avancegas.com. Dial in details are +44 (0) 2071 928 000 (UK and International), +1 631 510 7495 (US) or +47 23 96 02 64 (Norway). Please quote the passcode: 8359635. Phone lines will open 10 minutes before the conference call. For further queries, please contact: Peder C. G. Simonsen, CFO Tel: +47 22 00 48 15 Email: email@example.com ABOUT AVANCE GAS Avance Gas Holding Ltd operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs), operating a fleet of 14 modern VLGC. For more information about Avance Gas, please visit: www.avancegas.com Thi
SFL - Third Quarter 2019 Presentation21.11.2019 15:32:00 CET | Press release
Please find enclosed the presentation of the preliminary third quarter results to be held November 21, 2019, in the link below. Attachment SFL - Third Quarter 2019 Results Presentation
GOGL - Q3 2019 Presentation21.11.2019 13:10:00 CET | Press release
Please find enclosed the presentation of Golden Ocean Group Limited's third quarter 2019 results for today's webcast / conference call at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Q3 2019 Presentation
SDLP - Seadrill Partners LLC Announces Third Quarter 2019 Results21.11.2019 12:49:00 CET | Press release
Highlights Operating revenue of $184.8 million Operating income of $13.0 million Net loss of $54.2 million Adjusted EBITDA of $91.9 million Cash and cash equivalents of $653.6 million Economic utilization of 95% Order backlog of $512 million as of November 21, 2019 1 cent per common unit distribution for the third quarter of 2019 Financial Results Overview Total operating revenues for the third quarter were $184.8 million (2Q19: $178.5 million). The increase was primarily due to a full quarter of operations for the West Aquarius and West Capricorn, the West Auriga returning to normal operations, the West Polaris commencing its contract in Gabon and the early termination fee received for the West Vencedor. These were partially offset by early termination fees for the West Capricorn received in the second quarter not being repeated, idle time on the West Capella prior to the commencement of a new contract in September and a full quarter of idle time on the T-16 tender barge. Total operat